The domestic pharmaceutical market continues to grow, while domestic pharmaceutical company innovation capabilities are still weak. The first domestic chemical biopharmaceutical company listed on the New York Stock Exchange--Xiansheng Pharmaceutical Chairman Ren Jinsheng admits: "The data from our company's research institute shows that there is no Chinese pharmaceutical company in the global TOP200 new drug." However, this One issue is also being highly valued by the industry. During the “12th Five-Year Plan†period, drug innovation was included in the industry development priorities.
The funds are limited by the development of local pharmaceutical companies.
The weakness in the ability of local drug companies to innovate in new drugs has continued for a long time. All along, there have been few voices from local drug companies when it comes to new drug development. Compared with the top five pharmaceutical companies in the world, R&D investment is more than 12% of the total annual sales. The average R&D investment of Chinese drug companies is less than 5%, while the former’s annual sales are mostly 20 billion. Above the dollar.
It is understood that the funding issue is the fundamental reason for the weak ability of new drug innovation in Chinese pharmaceutical companies. According to Ren Jinsheng, Esound Pharmaceuticals has been undergoing 12 years of R&D and innovation in the world's first small molecule for the treatment of rheumatoid arthritis, which has been officially launched into clinical use a few days ago. And the listing of Edsing also cost hundreds of millions of RMB for 12 years. It is reported that Edsin has obtained the SF-DA1.1 new drug certificate and production approval certificate which is hailed as “Two Bombs and One Star†in the Chinese pharmaceutical field. It is an innovative drug with independent intellectual property rights and has also been incorporated into the Twelfth Five-Year Plan period of the Ministry of Science and Technology. Major science and technology special projects supported by "major new drug creation".
Policy support is expected to change the status quo
Even so, domestic pharmaceutical companies should be included in the global TOP200 list of new drugs. Ren Jinsheng believes that it may still take 8-10 years.
Contradicting the weak status of research and development of new drugs, China has become the third largest pharmaceutical market in the world and will soon be close to or surpassing Japan, becoming the second largest pharmaceutical market after the United States, and with the deepening of medical reforms, the Chinese pharmaceutical market It will get bigger and bigger.
This situation is getting the attention of the industry. It is reported that during the "12th Five-Year Plan" period, China will continue to increase investment in research and development of innovative drugs, and the central government will allocate 10 billion yuan of funds and 30 billion yuan in supporting funds for "a major new drug creation system." What is worth mentioning is that at present, the cost associated with the development of new drugs in China is still relatively low, and there are many types of diseases in China, which reduces the sampling cost during clinical trials. Relevant data show that the cost of new drug development in China is only about 1/25 of that of Western developed countries.
In 2011, the industry was known as the “explosion period of new drugsâ€. In addition to Synopsys Pharmaceuticals, Hengyang Pharmaceutical’s Hengyang Pharmaceuticals and Beida Pharmaceutical’s Camemina Pharmaceuticals successively obtained a new class of drug certificates. In addition, at present, China has 16 types of new drugs that have received certificates, 24 varieties are being declared, and nearly 500 promising new drugs are under study.
Related Links
Nobel Prize Winner Joins Guangpeng R&D Team
In order to increase its research and development capabilities, Guangpharm Group has recently appointed the Nobel Laureate of Physiology and Medicine, the father of “Viagraâ€, and Dr. Fried Mullard, a foreign member of the Chinese Academy of Sciences, to serve as Dean of the Guangzhou General Hospital of Medicine and to appoint a member of the Chinese Academy of Engineering. Zhong Nanshan became the honorary president of the hospital. The first phase of the fund pool, which reached 100 million yuan, was also launched at the same time. It is reported that the joining of these world's top “outside brains†will start the journey of TCM to international once again. This is also the first time that Chinese pharmaceutical companies have introduced the world's top new drug development team.
Li Chuyuan, general manager of Guangyao Pharmaceutical Group, said that in the future, R&D resources will be integrated into the Guangzhou Pharmaceutical Research Institute.
The funds are limited by the development of local pharmaceutical companies.
The weakness in the ability of local drug companies to innovate in new drugs has continued for a long time. All along, there have been few voices from local drug companies when it comes to new drug development. Compared with the top five pharmaceutical companies in the world, R&D investment is more than 12% of the total annual sales. The average R&D investment of Chinese drug companies is less than 5%, while the former’s annual sales are mostly 20 billion. Above the dollar.
It is understood that the funding issue is the fundamental reason for the weak ability of new drug innovation in Chinese pharmaceutical companies. According to Ren Jinsheng, Esound Pharmaceuticals has been undergoing 12 years of R&D and innovation in the world's first small molecule for the treatment of rheumatoid arthritis, which has been officially launched into clinical use a few days ago. And the listing of Edsing also cost hundreds of millions of RMB for 12 years. It is reported that Edsin has obtained the SF-DA1.1 new drug certificate and production approval certificate which is hailed as “Two Bombs and One Star†in the Chinese pharmaceutical field. It is an innovative drug with independent intellectual property rights and has also been incorporated into the Twelfth Five-Year Plan period of the Ministry of Science and Technology. Major science and technology special projects supported by "major new drug creation".
Policy support is expected to change the status quo
Even so, domestic pharmaceutical companies should be included in the global TOP200 list of new drugs. Ren Jinsheng believes that it may still take 8-10 years.
Contradicting the weak status of research and development of new drugs, China has become the third largest pharmaceutical market in the world and will soon be close to or surpassing Japan, becoming the second largest pharmaceutical market after the United States, and with the deepening of medical reforms, the Chinese pharmaceutical market It will get bigger and bigger.
This situation is getting the attention of the industry. It is reported that during the "12th Five-Year Plan" period, China will continue to increase investment in research and development of innovative drugs, and the central government will allocate 10 billion yuan of funds and 30 billion yuan in supporting funds for "a major new drug creation system." What is worth mentioning is that at present, the cost associated with the development of new drugs in China is still relatively low, and there are many types of diseases in China, which reduces the sampling cost during clinical trials. Relevant data show that the cost of new drug development in China is only about 1/25 of that of Western developed countries.
In 2011, the industry was known as the “explosion period of new drugsâ€. In addition to Synopsys Pharmaceuticals, Hengyang Pharmaceutical’s Hengyang Pharmaceuticals and Beida Pharmaceutical’s Camemina Pharmaceuticals successively obtained a new class of drug certificates. In addition, at present, China has 16 types of new drugs that have received certificates, 24 varieties are being declared, and nearly 500 promising new drugs are under study.
Related Links
Nobel Prize Winner Joins Guangpeng R&D Team
In order to increase its research and development capabilities, Guangpharm Group has recently appointed the Nobel Laureate of Physiology and Medicine, the father of “Viagraâ€, and Dr. Fried Mullard, a foreign member of the Chinese Academy of Sciences, to serve as Dean of the Guangzhou General Hospital of Medicine and to appoint a member of the Chinese Academy of Engineering. Zhong Nanshan became the honorary president of the hospital. The first phase of the fund pool, which reached 100 million yuan, was also launched at the same time. It is reported that the joining of these world's top “outside brains†will start the journey of TCM to international once again. This is also the first time that Chinese pharmaceutical companies have introduced the world's top new drug development team.
Li Chuyuan, general manager of Guangyao Pharmaceutical Group, said that in the future, R&D resources will be integrated into the Guangzhou Pharmaceutical Research Institute.
Medical 3D Mask Machine,Folding Mask Making Machine,Fold Flat 3D Mask Machine,Fold Flat Facemask Machine
Ningbo Dokee Mask Machine Co., Ltd. , https://www.autrendsmac.com